WL

Wei Li

Interim CEO of QuantX Biosciences

Boston, Massachusetts

Overview

Work Experience

QB

QuantX Biosciences

  • Interim CEO

    2022 - Current

Sirius Therapeutics

  • Founding Board Member

    2021

  • Interim CEO

    2021 - 2022

PT

Pediatrix Therapeutics

  • Founding Board Member

    2020

OcuMension Therapeutics

  • Founding Board Member

    2017

CP

CStone Pharmaceuticals

  • Founding Board Member

    2015

Creacion Ventures

  • Founding Partner

    2020

WuXi Healthcare Ventures

  • Founding Partner

    2015

FT

Frontera Therapeutics

  • Founding Board Member

    2019

  • Interim CEO

    2019 - 2021

DT

Dewpoint Therapeutics

  • Board Member

    2018 - 2020

KT

Kymera Therapeutics

  • Board Member

    2018 - 2020

Education

Investments

Frontera Therapeutics

Series B

Total Funding: $160M

Kymera Therapeutics

Series B

Total Funding: $200M

TCR2

Series B

Total Funding: $170M

Innovent Biologics

Series A

Total Funding: $150M

Relevant Websites